Suppr超能文献

间充质干细胞通过抑制 TGF-β-SMAD2/3 通路可逆性地将肌成纤维细胞去分化为成纤维样细胞。

Mesenchymal stem cells reversibly de-differentiate myofibroblasts to fibroblast-like cells by inhibiting the TGF-β-SMAD2/3 pathway.

机构信息

Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, People's Republic of China.

出版信息

Mol Med. 2023 Apr 25;29(1):59. doi: 10.1186/s10020-023-00630-9.

Abstract

BACKGROUND

Myofibroblasts (MFB), one of the major effectors of pathologic fibrosis, mainly derived from the activation of fibroblast to myofibroblast transition (FMT). Although MFBs were historically considered terminally differentiated cells, their potential for de-differentiation was recently recognized and implied with therapeutic value in treating fibrotic diseases, for instance, idiopathic pulmonary fibrosis (IPF) and post allogeneic hematopoietic stem cell transplantation bronchiolitis obliterans (BO). During the past decade, several methods were reported to block or reverse MFB differentiation, among which mesenchymal stem cells (MSC) have demonstrated potential but undetermined therapeutic values. However, the MSC-mediated regulation of FMT and underlying mechanisms remained largely undefined.

METHOD

By identifying TGF-β1 hypertension as the pivotal landmark during the pro-fibrotic FMT, TGF-β1-induced MFB and MSC co-culture models were established and utilized to investigate regulations by MSC on FMT in vitro. Methods including RNA sequencing (RNA-seq), Western blot, qPCR and flow cytometry were used.

RESULT

Our data revealed that TGF-β1 readily induced invasive signatures identified in fibrotic tissues and initiated MFB differentiation in normal FB. MSC reversibly de-differentiated MFB into a group of FB-like cells by selectively inhibiting the TGF-β-SMAD2/3 signaling. Importantly, these proliferation-boosted FB-like cells remained sensitive to TGF-β1 and could be re-induced into MFB.

CONCLUSION

Our findings highlighted the reversibility of MSC-mediated de-differentiation of MFB through TGF-β-SMAD2/3 signaling, which may explain MSC's inconsistent clinical efficacies in treating BO and other fibrotic diseases. These de-differentiated FB-like cells are still sensitive to TGF-β1 and may further deteriorate MFB phenotypes unless the pro-fibrotic microenvironment is corrected.

摘要

背景

肌成纤维细胞(MFB)是病理性纤维化的主要效应细胞之一,主要来源于成纤维细胞向肌成纤维细胞转化(FMT)的激活。尽管 MFB 曾被认为是终末分化细胞,但最近人们认识到它们具有去分化的潜力,并在治疗纤维化疾病方面具有潜在的治疗价值,例如特发性肺纤维化(IPF)和同种异体造血干细胞移植后细支气管炎性闭塞(BO)。在过去的十年中,已经报道了几种阻止或逆转 MFB 分化的方法,其中间充质干细胞(MSC)已显示出潜力,但治疗价值仍不确定。然而,MSC 介导的 FMT 调节及其潜在机制在很大程度上仍未得到阐明。

方法

通过鉴定 TGF-β1 高血压作为促纤维化 FMT 的关键标志,建立了 TGF-β1 诱导的 MFB 和 MSC 共培养模型,并用于体外研究 MSC 对 FMT 的调节作用。方法包括 RNA 测序(RNA-seq)、Western blot、qPCR 和流式细胞术。

结果

我们的数据显示,TGF-β1 容易诱导纤维化组织中鉴定的侵袭特征,并在正常 FB 中启动 MFB 分化。MSC 通过选择性抑制 TGF-β-SMAD2/3 信号,可逆地将 MFB 分化为一群 FB 样细胞。重要的是,这些增殖增强的 FB 样细胞仍然对 TGF-β1 敏感,并可重新诱导为 MFB。

结论

我们的研究结果强调了 MSC 通过 TGF-β-SMAD2/3 信号介导的 MFB 去分化的可逆性,这可能解释了 MSC 在治疗 BO 和其他纤维化疾病中的疗效不一致。这些去分化的 FB 样细胞仍然对 TGF-β1 敏感,除非纠正促纤维化微环境,否则可能进一步恶化 MFB 表型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0378/10131436/8d8274a5f6bf/10020_2023_630_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验